Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse.
Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse.
复制标题
基于 Sm-p80 的 DNA 疫苗由人类使用批准的载体 VR1020 制成，可保护小鼠免受曼氏血吸虫的攻击感染。
DOI：
10.1111/j.1365-3024.2009.01181.x
复制
发表时间：
2010
影响因子：
2.2
通讯作者：
Siddiqui,AA
中科院分区：
文献类型：
--
作者：
Zhang,W;Ahmad,G;Torben,W;Siddiqui,AA
虽然有一种有效的药物（吡喹酮）可用于治疗血吸虫病，但这种疾病仍然蔓延不减，在76个国家猖獗。迄今为止，通过吡喹酮治疗进行控制不足以减少疾病传播。因此，除了其他战略，例如改善卫生条件和引进新药之外，疫苗对成功控制并最终根除血吸虫病至关重要。为此，我们靶向了一种功能重要的抗原，Sm-p80作为候选疫苗。在这项研究中，Sm-p80的全长cDNA克隆到VR 1020中，VR 1020是FDA批准的人用载体。在鼠模型中测试了该疫苗制剂的保护效力。Sm-p80-VR 1020疫苗制剂能够诱导蠕虫负荷降低47%。从接种疫苗动物获得的样品的血清学显示强烈的抗体应答，包括IgG及其所有亚型、IgM和伊加。通过RT-PCR分析确定，应答重组Sm-p80的脾细胞产生代表Th 1、Th 2和Th 17类型的广谱细胞因子。这些发现进一步加强了Sm-p80分子作为肠血吸虫病候选疫苗的重要性。
Although there is an effective drug (praziquantel) available for the treatment of schistosomiasis, yet the disease is still spreading unabated and is rampant in 76 countries. Control via praziquantel treatment has so far been insufficient in reducing the disease transmission. Therefore, a vaccine in addition to other strategies, for example, improving sanitation and introduction of new drugs are essential to successfully control and eventually eradicate schistosomiasis. To this effect, we have targeted a functionally important antigen, Sm‐p80 as a vaccine candidate. In this study, full length cDNA of Sm‐p80 was cloned in VR1020, a FDA approved vector for human use. The protective efficacy of this vaccine formulation was tested in a murine model. Sm‐p80‐VR1020 vaccine formulation was able to induce 47% reduction in worm burden. Serology on samples obtained from vaccinated animals revealed a strong antibody response which included IgG and all of its subtypes, IgM and IgA. Proliferating splenocytes in response to recombinant Sm‐p80 produced a wide spectrum of cytokines representing Th1, Th2 and Th17 types, as ascertained via RT‐PCR analysis. These findings further strengthen the importance of Sm‐p80 molecule as a vaccine candidate for intestinal schistosomiasis.